- Europe
- Americas
- Asia and Middle East
- Africa and Oceania
In hospital pharmacies, a large number of drug doses have to be individually compounded and dispensed on a daily basis. A fully automated infusion compounding system enhances quality during this sensitive task and avoids health and safety risks for clinical staff arising from skin contact with preparations that are often toxic.
The aseptic preparation of drugs such as infusion solutions is one of the more complex tasks in pharmaceutical dispensing. In addition to creating the right conditions for production, the right technology for automation of the process has to be identified and implemented.
ARxIUM is a multinational company that offers hospitals and pharmacies around the world a highly efficient automation solution for the filling and compounding of infusions that meet the highest standards in terms of quality and quantity. ARxIUM set out to establish a technology that would be synonymous with Pharma 4.0 and able to operate within ISO Class 5 or higher.
One solution that has been available on the market for some time now goes by the name of RIVA™. This is a fully automated infusion compounding system that incorporates a six-axis robot of the TX60L-series. The pioneering technology that has gone into the production system, ensures that it is already primed for the regulatory requirements that will apply in the pharmaceutical industry of tomorrow with regard to safety, effectiveness and, above all, precision.
The Stäubli TX60L deployed in this case is a Stericlean model. This hydrogen peroxide-resistant version of the robot has some obvious modifications, including specially treated surfaces that permit it to be used in aseptic environments. Even more significantly, the enclosed structure of the Stericlean model and its IP65 credentials made it the ideal choice. The high-precision Stäubli robot is able to manage the filling of infusion bags with any dosage of medication quickly, precisely and reliably. In a three-shift operation, it has significantly increased the capacity utilization and throughput of the RIVA™ cell.
A strong argument in favor of this robot was that Stäubli is the only manufacturer to equip its robots with proprietary drive technology which is characterized not only by superior precision and dynamics, but also by long service intervals and a service life that is far above average.
The use of the robot can significantly reduce errors and contamination. Furthermore, health and safety risks for the clinical staff who handle the preparations, some of which are toxic, have now been completely excluded. The partnership meanwhile goes from strength to strength: at ARxIUM a large number of TX60L robots and controllers have since been installed. More than eight million doses have been compounded by RIVA™ units to date – a colossal figure.
For many users, the robotic cell has made such a favorable impression that they have decided to invest in additional units.
